CAM-cytarabine, aclarubicin plus macrophage colony-stimulating factor in the treatment of acute myelogenous leukemia with trilineage dysplasia: usefulness of in vitro apoptosis in leukemic cells.
A 67-year-old woman was treated for acute myelogenous leukemia with trilineage dysplasia (AML-TLD) by combination chemotherapy with cytarabine, aclarubicin plus macrophage colony-stimulating factor (M-CSF) (referred to as CAM therapy). Complete remission was achieved after two courses of CAM therapy. After coculture of her bone marrow mononuclear cells with M-CSF in vitro, differentiation of leukemic cells into macrophages with apoptotis was observed. This case confirms an earlier report that an effect of M-CSF inducible by differentiation with apoptotic phenomena, against human leukemic cells was shown both in vitro and in vivo when achieving complete remission.
Mori
M
M
Department of Hematology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi 329-0498, Japan.
Hatake
K
K
Tanaka
M
M
Takatoku
M
M
Matsumoto
Y
Y
Uchida
M
M
Kametaka
M
M
Nagai
T
T
Terui
Y
Y
Tomizuka
H
H
Muroi
K
K
Ozawa
K
K
D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001854:Bone Marrow Cells / Q000473:pathology; D018920:Coculture Techniques; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy*; D007963:Leukocytes, Mononuclear / Q000473:pathology; D016173:Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D015703:Antigens, CD; D016173:Macrophage Colony-Stimulating Factor